The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups (Q34265256)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 1, 2003

The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups

Language	Label	Description	Also known as
English	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups	scientific article published on October 1, 2003	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

6

object named as

Petra Muus

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lambertus Kiemeney

4

object named as

Bart A. L M. Kiemeney

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

author name string

Margriet Oosterveld

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ashuman Catik

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Shulamiet H. Wittebol

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

Wim A. J G. Lemmens

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

Anton V. M B. Schattenberg

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

Theo J. M. de Witte

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

language of work or name

0 references

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

full work available at URL

https://doi.org/10.1046/j.1365-2141.2003.04544.x

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510946

14 March 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.2003.04544.x

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.2003.04544.x

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

123

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

81-89

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04544.X

21 January 2018

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system

2

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution

3

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system.

11

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome

12

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study.

13

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Application of the International Prognostic Scoring System for myelodysplastic syndromes.

14

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases

15

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Myelodysplastic syndromes: a scoring system with prognostic significance

16

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Myelodysplastic syndromes

18

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

20

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems

21

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

24

1 reference

10.1046/J.1365-2141.2003.04544.X

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04544.X

14 March 2024

Identifiers

10.1046/J.1365-2141.2003.04544.X

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34265256&oldid=2103801757"